文献速递消化道肿瘤放疗放疗物理与技术

同步立体定向体部放疗联合奈非那韦治疗局部晚期交界可切除或不可切除胰腺腺癌的Ⅰ期试验

Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
PubMed 文献 · Radiother Oncol · 2018-12-20

这项Ⅰ期试验(NCT01068327)评估同步立体定向体部放疗(SBRT)联合HIV蛋白酶抑制剂奈非那韦(NFV)治疗交界可切除或不可切除胰腺癌的最大耐受剂量及结局。46例入组、39例接受方案治疗,最大耐受剂量为40 Gy/奈非那韦1250 mg每日两次×5周,中位总生存期14.4个月;作者认为该方案可行且安全,但建议仔细关注治疗计划参数以减少晚期消化道出血。

要点

  • 最大耐受剂量为SBRT 40 Gy联合奈非那韦1250 mg每日两次×5周。
  • 39例接受方案治疗者中16例(41%)在SBRT期间及之后1个月发生任何≥2级事件。
  • 中位总生存期14.4个月,6例(15%)局部复发,中位局部无失败生存期未达到。

核心结论

  • 同步SBRT(40 Gy)联合奈非那韦(1250 mg每日两次)治疗局部晚期胰腺癌可行且安全。
  • 作者建议仔细关注治疗计划参数以减少晚期消化道出血的发生率。

研究设计与样本

  • Ⅰ期剂量递增试验(NCT01068327),入组交界可切除或不可切除胰腺癌患者。
  • 初诊影像、病理确认及分期腹腔镜后,受试者先接受3个周期每3周一次的吉西他滨/亚叶酸钙/氟尿嘧啶方案。
  • 无影像学进展者接受5次SBRT联合奈非那韦治疗,剂量递增水平依次为25 Gy/625 mg每日两次×3周、25 Gy/1250 mg每日两次×3周、30 Gy/1250 mg每日两次×3周、35 Gy/1250 mg每日两次×3周、35 Gy/1250 mg每日两次×5周、40 Gy/1250 mg每日两次×5周。
  • SBRT后如可切除则行胰十二指肠切除术,否则给予吉西他滨/亚叶酸钙/氟尿嘧啶。
  • 2008年10月至2013年5月共46例入组,其中39例接受方案导向治疗。

主要发现

  • 39例接受方案治疗者中16例(41%)在SBRT期间及之后1个月发生任何≥2级事件。
  • 4例3级事件及2例4级事件均发生于初始剂量水平的一名患者。
  • 5例发生晚期消化道出血(2例肠系膜上动脉假性动脉瘤、1例疾病进展、1例下消化道、1例部位不明)。
  • 中位总生存期为14.4个月。
  • 6例(15%)局部复发,中位局部无失败生存期未达到;中位远处无失败生存期为11个月,中位全无失败生存期为10个月。

关键数值与推荐

  • 最大耐受剂量为40 Gy/奈非那韦1250 mg每日两次×5周。
  • 剂量递增水平包括25 Gy/625 mg每日两次×3周、25 Gy/1250 mg每日两次×3周、30 Gy/1250 mg每日两次×3周、35 Gy/1250 mg每日两次×3周、35 Gy/1250 mg每日两次×5周及40 Gy/1250 mg每日两次×5周。

临床怎么用

  • 作者认为同步SBRT(40 Gy)联合奈非那韦(1250 mg每日两次)治疗局部晚期胰腺癌可行且安全。
  • 作者建议仔细关注治疗计划参数以减少晚期消化道出血的发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The HIV protease inhibitor nelfinavir (NFV) displays notable radiosensitizing effects. There have been no studies evaluating combined stereotactic body radiotherapy (SBRT) and NFV for borderline/unresectable pancreatic cancer. The primary objective of this phase I trial (NCT01068327) was to determine the maximum tolerated SBRT/NFV dose, and secondarily evaluate outcomes. METHODS: Following initial imaging, pathologic confirmation, and staging laparoscopy, subjects initially received three 3-week cycles of gemcitabine/leucovorin/fluorouracil; patients without radiologic progression received 5-fraction SBRT/NFV. Dose escalation was as follows: (1) 25 Gy/625 mg BID ×3wks; (2) 25 Gy/1250 mg BID ×3wks; (3) 30 Gy/1250 mg BID ×3wks; (4) 35 Gy/1250 mg BID ×3wks; (5) 35 Gy/1250 mg BID ×5wks; and (6) 40 Gy/1250 mg BID ×5wks. Pancreaticoduodenectomy was performed thereafter if resectable; if not, gemcitabine/leucovorin/fluorouracil was administered. RESULTS: Forty-six patients enrolled (10/2008-5/2013); 39 received protocol-directed therapy. Sixteen (41%) experienced any grade ≥2 event during and 1 month after SBRT. Four grade 3 and both grade 4 events occurred in a single patient at the initial dose level. 40 Gy/1250 mg BID ×5wks was the maximum tolerated dose. Five patients had late gastrointestinal bleeding (n = 2 superior mesenteric artery pseudo-aneurysm, n = 1 disease progression, n = 1 lower GI tract, n = 1 unknown location). The median overall survival was 14.4 months. Six (15%) patients recurred locally; median local failure-free survival was not reached. The median distant failure-free survival was 11 months, and median all failure-free survival was 10 months. CONCLUSIONS: Concurrent SBRT (40 Gy)/NFV (1250 mg BID) for locally advanced pancreatic cancer is feasible and safe, although careful attention to treatment planning parameters is recommended to reduce the incidence of late gastrointestinal bleeding.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lin C, Verma V, Ly QP, et al. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiother Oncol. 2018. PMID: 30825970. doi:10.1016/j.radonc.2018.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。